Deep lymph node enlargement and renal failure caused by hypercalcemia ‑associated sarcoidosis: A case report
Exp Ther Med. 2024 Mar 27;27(5):235. doi: 10.3892/etm.2024.12524. eCollection 2024 May.ABSTRACTSarcoidosis is a rare disease that severely affects the lungs and superficial lymph nodes. In addition, this disease can also affect the skin, eyes and kidneys to varying degrees. The present report described a 32-year-old male patient who was admitted to Renmin Hospital of Wuhan University (Wuhan, China) due to joint pain in the extremities. He was diagnosed with uncorrectable hypercalcemia. A lymph node biopsy revealed the hypercalcemia to be associated with sarcoidosis, with the patient also demonstrating renal failure and lym...
Source: Experimental and Therapeutic Medicine - April 17, 2024 Category: General Medicine Authors: Zezhou Liu Zhigang Tang Jingping Yuan Ke Su Yonghong Jian Hongyan Liu Source Type: research
Prognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: An observational restrospective study
CONCLUSION: PET vascular activity scores at diagnosis and at follow-up PET/CT performed outside a period of GCA activity do not display high performance to predict the occurrence of subsequent relapse in LV-GCA patients.PMID:38627183 | DOI:10.1016/j.ejim.2024.03.037 (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - April 16, 2024 Category: Internal Medicine Authors: Anne-Claire Billet Thomas Thibault Éric Liozon Hubert De Boysson Laurent Perard Olivier Espitia Aur élie Daumas Quentin Gomes De Pinho C écile-Audrey Durel Arnaud Hot Boris Bienvenu S ébastien Humbert Claude Bachmeyer Sabine Mainbourg Thomas Sen é He Source Type: research
Prognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: An observational restrospective study
CONCLUSION: PET vascular activity scores at diagnosis and at follow-up PET/CT performed outside a period of GCA activity do not display high performance to predict the occurrence of subsequent relapse in LV-GCA patients.PMID:38627183 | DOI:10.1016/j.ejim.2024.03.037 (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - April 16, 2024 Category: Internal Medicine Authors: Anne-Claire Billet Thomas Thibault Éric Liozon Hubert De Boysson Laurent Perard Olivier Espitia Aur élie Daumas Quentin Gomes De Pinho C écile-Audrey Durel Arnaud Hot Boris Bienvenu S ébastien Humbert Claude Bachmeyer Sabine Mainbourg Thomas Sen é He Source Type: research
Population pharmacokinetics and exposure –response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
AbstractPolatuzumab vedotin is a CD79b-directed antibody –drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The phase III POLARIX study (NCT03274492) evaluated polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) as first-line treatment of diffuse la rge B-cell lymphoma (DLBCL). To examine dosing decisions for this regimen, population pharmacokinetic (popPK) analysis, using a previously developed popPK model, and exposure–response (ER) analysis, were performed. The popPK analysis showed no clinically meaningful rela...
Source: CPT: Pharmacometrics and Systems Pharmacology - April 16, 2024 Category: Drugs & Pharmacology Authors: Rong Deng,
Leonid Gibiansky,
Tong Lu,
Christopher R. Flowers,
Laurie H. Sehn,
Qi Liu,
Priya Agarwal,
Michael Z. Liao,
Randall Dere,
Calvin Lee,
Gabriel Man,
Jamie Hirata,
Chunze Li,
Dale Miles Tags: ARTICLE Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
Intestinal Langerhans cell histiocytosis presenting with symptoms similar to inflammatory bowel disease: a case report
CONCLUSION: The clinical symptoms of Langerhans cell histiocytosis involving the gastrointestinal tract are not specific and may resemble symptoms observed in inflammatory bowel disease and other primary gastrointestinal tumors. Therefore, in cases of infants presenting with inflammatory gastrointestinal symptoms that do not resolve after treatment, a biopsy is essential to obtain a differential diagnosis.PMID:38605931 | PMC:PMC11007090 | DOI:10.3389/pore.2024.1611705 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Yuqing Liu Zhenwei Chen Lu Wang Baizhou Li Source Type: research
Intestinal Langerhans cell histiocytosis presenting with symptoms similar to inflammatory bowel disease: a case report
CONCLUSION: The clinical symptoms of Langerhans cell histiocytosis involving the gastrointestinal tract are not specific and may resemble symptoms observed in inflammatory bowel disease and other primary gastrointestinal tumors. Therefore, in cases of infants presenting with inflammatory gastrointestinal symptoms that do not resolve after treatment, a biopsy is essential to obtain a differential diagnosis.PMID:38605931 | PMC:PMC11007090 | DOI:10.3389/pore.2024.1611705 (Source: Cell Research)
Source: Cell Research - April 12, 2024 Category: Cytology Authors: Yuqing Liu Zhenwei Chen Lu Wang Baizhou Li Source Type: research
Efficacy and Safety of Methylprednisolone Pulse Therapy and Conventional Oral Prednisone for Pediatric Patients With Nephrotic Syndrome
CONCLUSIONS: High-dose methylprednisolone pulse therapy demonstrated better efficacy in treating pediatric NS patients, showing a shorter time to symptom relief, but it may also entail a higher risk of adverse reactions compared to conventional oral high-dose prednisone. Clinicians should consider the specific circumstances and needs of pediatric patients when selecting a treatment.PMID:38607215 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - April 12, 2024 Category: Complementary Medicine Authors: Mingfang Liu Yingjian Cai Source Type: research
A Rare Case of Benign Recurrent Intrahepatic Cholestasis Initially Diagnosed in Middle-age
CONCLUSION: The comprehensive diagnosis of a middle-aged male patient with BRIC-2, which involved extensive radiological, hematological, and genetic investigations, informed a tailored tapering prednisone regimen, highlighting the importance of personalized medicine in managing atypical presentations of this rare cholestatic disorder.PMID:38607191 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - April 12, 2024 Category: Complementary Medicine Authors: Fang Liu Wei Li Ming-Gang Zhang Zhen-Mei Song Xiao-di Wang Xiu-Hong Wang Shi-Yu Du Source Type: research
Intestinal Langerhans cell histiocytosis presenting with symptoms similar to inflammatory bowel disease: a case report
CONCLUSION: The clinical symptoms of Langerhans cell histiocytosis involving the gastrointestinal tract are not specific and may resemble symptoms observed in inflammatory bowel disease and other primary gastrointestinal tumors. Therefore, in cases of infants presenting with inflammatory gastrointestinal symptoms that do not resolve after treatment, a biopsy is essential to obtain a differential diagnosis.PMID:38605931 | PMC:PMC11007090 | DOI:10.3389/pore.2024.1611705 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Yuqing Liu Zhenwei Chen Lu Wang Baizhou Li Source Type: research
